Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. (Israel) is dated March 29, 2017. The document serves as a notice of the Company's Annual General Meeting of Shareholders scheduled for May 11, 2017. The filing incorporates by reference the meeting notice posted on the Company's website and does not contain a financial report for a specific fiscal period.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document notes that shareholders will have an opportunity to review financial statements for the fiscal year ended December 31, 2016, at the upcoming meeting, but those figures are not included in this text.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses on corporate governance actions and agenda items for the shareholder meeting rather than operational or financial performance updates.
Guidance, Outlook, and Corporate Actions
The filing outlines the agenda for the Annual General Meeting, which includes the following key items:
- Auditor Appointment: Appointment of Kesselman & Kesselman (PricewaterhouseCoopers International Limited) as auditors for 2017.
- Board Elections: Re-election of Dror Ben-Asher and Rick D. Scruggs (3-year terms); election of Nicholas A. Weinstein (3-year term); re-election of Ofer Tsimchi (1-year term) and Nurit Benjamini (2-year term).
- Articles of Association Amendments: Increasing the maximum number of directors to 11; clarifying voting requirements for directors with terms under three years; and provisions regarding early expiration of terms for directors nominated by investors who purchased at least $15 million in ADSs and warrants in the December 27, 2016 offering if beneficial ownership levels are not met.
- Executive Compensation: Approval of Dror Ben-Asher's engagement as Chairman and CEO, revisions to his compensation terms, and option grants to non-executive directors.
- Equity Plan: Approval of the Amended and Restated Award Plan (2010).
Voting Details: The record date is April 3, 2017. The final date to submit a position statement is April 30, 2017, and the last date to submit a voting instrument is May 11, 2017, at 11:00 a.m. Israel time.
Key Facts for Investor Verification
- Verify the outcome of the shareholder votes on the Board of Directors and the amendments to the Articles of Association at the May 11, 2017 meeting.
- Review the full financial statements for the fiscal year ended December 31, 2016, which are referenced but not included in this filing.
- Confirm the specific terms of the revised compensation package for CEO Dror Ben-Asher.
- Monitor the beneficial ownership levels of the investor who purchased $15 million in the December 2016 offering to determine if the early expiration clause for their nominated director is triggered.